Squamous Cell Carcinoma of Esophagus Clinical Trial
Official title:
Application of ctDNA-MRD in the Prediction of Curative Effect, Recurrence Monitoring and Prognosis Evaluation of Esophageal Squamous Cell Carcinoma (ESCC) During Perioperative Treatment
The purpose of this study is to observe and evaluate the correlation between ctDNA-MRD and the therapeutic effect and prognosis of stage II-IVA operable esophageal squamous cell carcinoma.
ESCC patients with II-IVA resection will undergo MRD examination at the following time: the first examination is before the operation, the second examination is 7-10 days after the operation, and then 1 month after the operation, 2 weeks after the end of adjuvant treatment (if available), the follow-up period (every 3 months if there is no postoperative treatment) and the progress (the progress of the disease confirmed by the researcher), the patients will receive close MRD monitoring to evaluate the correlation between ctDNA-MRD and therapeutic efficacy and prognosis. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04196075 -
The Effect of Andrographis Paniculata (AP) on Palliative Management of Advanced Esophageal Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT02353936 -
A Phase II Trial of Afatinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus
|
Phase 2 | |
| Withdrawn |
NCT02033538 -
Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Squamous Cell Carcinoma of Esophagus
|
Phase 2 | |
| Terminated |
NCT01248299 -
Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer.
|
Phase 2 | |
| Withdrawn |
NCT02041819 -
Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of Esophagus
|
Phase 2 | |
| Completed |
NCT00165490 -
Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer
|
Phase 2 |